Re-treating brain tumor with radioactive liposome after prior dose
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 trial tests whether a radioactive treatment delivered in tiny fat “packets” is safe and tolerable when given again to people whose glioma (brain tumor) came back after a previous similar treatment. It also looks at how well this re-treatment works in carefully selected patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and be able to sign informed consent.
- Your brain tumor must be a glioma (brain cancer) proven by biopsy, and it must have progressed after your prior 186RNL treatment (Grade III or IV allowed).
- You must be at least 90 days since your last 186RNL dose.
- You must be planned for a stereotactic brain biopsy as part of standard care.
- If you take anti-seizure or anti-swelling steroid medicines, your dose must be stable (and seizures must be controlled) before starting, for set time periods.
- Your blood counts, kidney, and liver tests must be within allowed limits, and you must have enough tumor area in the scan that fits the treatment plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a drug made of tiny fat-like particles carrying rhenium for recurrent (coming back) high-grade glioma. It mainly checks safety and the highest tolerable dose, and it also looks for signs the treatment may slow tumor growth.
This trial tests a new way to deliver radiation therapy for people whose brain tumor (glioma) has come back after earlier treatment. Instead of standard radiation, it uses very low doses given in pulses, which may be safer for patients who have already had radiation to the head.
This trial tests a new type of proton radiation therapy given at a lower dose rate to treat brain tumors that have come back after previous radiation. The goal is to see if it's safe and effective.
This trial tests a radioactive drug (Rhenium-186) injected directly into the brain tumor to see the highest safe dose for children and young adults with ependymoma or high-grade glioma that has come back or is not responding to standard treatments. It may help shrink the tumor without needing surgery right away.
This trial tests a radioactive drug that targets a protein on tumor blood vessels to treat glioblastoma that has come back after standard treatment. It may help shrink tumors or slow their growth.
This early-stage trial tests a new radioactive drug called [177Lu]Lu-XT771 injected directly into the brain cavity after glioblastoma surgery. It measures whether the drug is safe and helps slow tumor regrowth in patients whose cancer has come back after earlier treatments.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.